Tempest Therapeutics Files Initial Beneficial Ownership Statement for CFO
Tempest Therapeutics filed an initial beneficial ownership statement for CFO, Treasurer and Corporate Secretary Stephanie Horn-Warnock.
Related stories
Flight Cancellations Mount at DFW and Love Field After FAA Ground Stop
Cancellations mounted Saturday morning at DFW International Airport and Dallas Love Field after an FAA ground stop was lifted.
M impact | EQUITY | Nov 14, 2026, 07:03 PM UTC
Thousands of US Flights Canceled and Delayed as Air Travel System Recovers
Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown.
M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC
Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound
The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds
Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm
Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC
Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial
At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC